Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | HRH2 | P25021 | 13/20 | 0.36 |
| ▸ | HRH1 | P35367 | 13/20 | 0.36 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26501256 | 0.95 | HRH2 (0.39) | HRH2HRH1DRD2HRH3 | |
| SCHEMBL26501314 | 0.88 | HRH2 (0.42) | HRH2HRH1DRD2 | |
| SCHEMBL26743342 | 0.85 | HRH2 (0.40) | GAAHRH2HRH1DRD2ALOX15 | |
| SCHEMBL26742004 | 0.84 | GAA (0.39) | GAAHRH2HRH1DRD2ALOX15 | |
| SCHEMBL26504879 | 0.84 | HRH2 (0.38) | HRH2HRH1DRD2HRH3 | |
| SCHEMBL26501255 | 0.78 | ALDH1A1 (0.39) | GAAHRH2HRH1DRD2ALOX15 | |
| SCHEMBL26501230 | 0.78 | SIGMAR1 (0.39) | HRH2HRH1DRD2 | |
| SCHEMBL26746316 | 0.77 | GAA (0.42) | GAAALOX15TSHRHSD17B10ALDH1A1 | |
| SCHEMBL470994 | 0.76 | EPHX2 (0.44) | HRH2HRH1ALDH1A1 | |
| SCHEMBL26742006 | 0.76 | GAA (0.41) | GAAALOX15TSHRHSD17B10HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230321253-A1 | BIFUNCTIONAL COMPOUNDS AND PHARMACEUTICAL USES THEREOF | Risen (Suzhou) Pharma Tech Co., Ltd. (CN) | 2023-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230321253-A1 | BIFUNCTIONAL COMPOUNDS AND PHARMACEUTICAL USES THEREOF | KRAS, MDM2, NRAS | GAA 1149/4885HRH2 3216/4885HRH1 2655/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.